How High-Quality Biospecimens Support HIV Diagnostic Validation: Insights from a Published Cross-Platform Study
High-quality HIV biospecimens are essential for developing and validating accurate diagnostic assays. A recent peer-reviewed study published in the Journal of Clinical Virology Plus demonstrated excellent analytical and clinical agreement for the Siemens Healthineers HIV Antigen/Antibody Combo assay across multiple automated testing platforms. The study utilized well-characterized HIV-positive and HIV-negative serum specimens, including samples sourced from Boca Biolistics, highlighting the critical role of quality biospecimens in assay verification and clinical validation. Boca Bio supports diagnostics manufacturers, biotechnology companies, and clinical research organizations with customized HIV biospecimen procurement, central laboratory services, and clinical research solutions that help accelerate infectious disease diagnostic development and regulatory submissions.
Beyond Recruitment: Why High-Quality Clinical Data Is the New Competitive Advantage
Clinical trial success depends on more than patient recruitment. Learn why high-quality clinical data, biospecimen integrity, and operational excellence are becoming critical competitive advantages in modern clinical research.
How to Evaluate Biospecimen and Lab Testing Services for Translational Research
Selecting the right biospecimen and lab testing services partner is critical for generating reliable data, accelerating timelines, and supporting regulatory success. This blog outlines seven key factors pharma and IVD teams should evaluate, including biospecimen access, CLIA-certified testing, biomarker expertise, regulatory experience, data traceability, and integrated laboratory services. Learn how the right partner can help streamline research operations and improve study outcomes.
Accelerating Biomarker Discovery Through High-Quality Biospecimen Collection
Learn how Boca Bio helped a next-generation drug discovery company complete a chronic migraine biomarker study within two months through high-quality biospecimen collection, multi-site patient recruitment, and precise sample handling that preserved biomarker integrity.
Point-of-care comparative study supports successful 510(k) clearance with CLIA waiver designation
A global diagnostics company accelerated FDA approval and market launch for 12 infectious disease tests by partnering with Boca Bio. Facing delays from slow, inflexible vendors, the company needed rapid sample sourcing, faster testing, and agile clinical support. Boca Bio delivered results up to 12x faster, reduced site activation timelines by half, and ensured compliance with strict FDA deadlines—enabling earlier market entry and improved revenue outcomes.
How a Global Diagnostics Company Accelerated FDA Approval and Market Launch with Boca Bio
A global diagnostics company accelerated FDA approval and market launch for 12 infectious disease tests by partnering with Boca Bio. Facing delays from slow, inflexible vendors, the company needed rapid sample sourcing, faster testing, and agile clinical support. Boca Bio delivered results up to 12x faster, reduced site activation timelines by half, and ensured compliance with strict FDA deadlines—enabling earlier market entry and improved revenue outcomes.
Rapid Serum Procurement for Vaccine Trials
Accelerate vaccine development with rapid serum procurement from recently immunized subjects. Boca Biolistics provides high-quality, well-characterized serum samples with fast turnaround times, scalable recruitment, and comprehensive clinical metadata. Supporting vaccine trials and immunogenicity studies, our CLIA- and CAP-certified biorepository ensures compliance with HIPAA and 21 CFR Part 11 standards. Generate reliable immune response data within critical post-immunization windows and advance biomarker analysis, vaccine benchmarking, and clinical research outcomes.